Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

City of Hope

Status: Terminated

Conditions: Graft Versus Host Disease; Multiple Myeloma and Plasma Cell Neoplasm; Infection; Neuroblastoma; Myelodysplastic-Myeloproliferative Diseases; Chronic Myeloproliferative Disorders; Therapy-related Toxicity; Lymphoma; Leukemia; Myelodysplastic Syndromes

Treatments: Procedure: allogeneic hematopoietic stem cell transplantation; Biological: immunosuppressive therapy; Other: immunological diagnostic method

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00813501

P30CA033572 (U.S. NIH Grant/Contract)

CDR0000628793 (Registry Identifier)

CHNMC-07200

07200

Details and patient eligibility

About

RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.

PURPOSE: This clinical trial is studying an immunologic diagnostic blood test to see how well it works in predicting side-effects in patients with hematologic cancer or other disorders who have undergone a donor stem cell transplant.

Full description

OBJECTIVES:

• To evaluate the ability of the ImmuKnow® test to predict the onset and severity of acute or chronic graft-versus-host disease and/or measure the clinical effects of treatment.
• To evaluate the ability of the ImmuKnow test to predict the clinical response to immunosuppressive therapy.
• To evaluate the ability of the ImmuKnow test to predict infections among patients.

OUTLINE: Beginning on day 14 after allogeneic hematopoietic stem cell transplantation (HSCT), patients undergo blood sample collection at least once weekly for the first 100 days and then once to twice monthly for up to 1 year, in the absence of graft-versus-host disease (GVHD). If chronic or acute GVHD develops after day 100, more frequent blood sampling may occur. Blood sample collection is coordinated with the time of regular clinic visits to allow for evaluation of the clinical events recorded 2 weeks before and after the blood draw date. Blood samples are analyzed by the Cylex® and ImmuKnow® assays to measure global T-cell immune function and responsiveness to alterations in immunosuppressive post-HSCT therapy. Assay data obtained during the first 3 weeks and other post-transplant periods will be evaluated for possible correlations with clinical endpoints (i.e., GVHD incidence, rate of infection, and response to immunosuppressive therapy) to assess the predictive value of the assay.

Enrollment: 60 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Diagnosis of a hematologic cancer or other disease
• Undergoing allogeneic hematopoietic stem cell transplantation

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics